Dr. Charles Adelson is a registered patent agent in DLA Piper’s Prosecution practice, where he advises clients on patent portfolio and prosecution strategies as well as freedom-to-operate, invalidity, and noninfringement analyses. Charles’ practice focuses on patent prosecution spanning life sciences, chemical, and diagnostic technologies, including biologic and small molecule therapeutics, antibody-drug conjugates biomolecule and organism engineering, transfection methods, novel polysaccharides, and biological assays. 

During his doctoral studies, Charles correlated enzyme structure and function in redox-active biological sites to guide protein and synthetic catalyst design and to elucidate disease-mutation relationships. His research involved spectroscopic, magnetic, and biological characterization techniques, as well as quantum mechanical theory formulation for protein-metal ion covalency quantitation. During his Ph.D., Charles also prospected a CO2 remediation technology in the Stanford Climate Ventures startup incubator.

Charles is not a lawyer.